News | August 06, 2025
Indegene posts Q1 net profit higher by 33% YoY to Rs. 116.4 Cr
The operating profit (EBITDA) rose 20.7% to Rs. 156.4 crore
The operating profit (EBITDA) rose 20.7% to Rs. 156.4 crore
Athena is also exploring the use of this technology for expanded carrier screening
The system, called GeneAgent, cross-checks its own initial predictions for accuracy against information from established, expert-curated databases
Elevidys is currently the only approved gene therapy that targets the root cause of Duchenne
The Genexus platform enables Next-Generation Sequencing with significantly faster turnaround times
The latest BioE3 policy builds the framework for high-performance biomanufacturing to propel the development and production
Kushwaha previously served as Chief Digital & Information Officer at Jubilant Ingrevia Limited
GSK and Hengrui Pharma enter agreements to develop up to 12 innovative medicines across Respiratory, Immunology & Inflammation and Oncology
Reported EBITDA up by 19% year-on-year with reported EBITDA margin at 25%
FDA requests Sarepta Therapeutics to suspend distribution of Elevidys and places clinical trials on hold for multiple gene therapy products following 3 deaths
Subscribe To Our Newsletter & Stay Updated
